A novel antibacterial non-leaching bone cement based 3,4-dichloro-5-hydroxyfuran-2(5 H )-one (DHF) was synthesized. We refer to it as DHF-MAA cement, and it exhibits excellent antibacterial activity, compressive properties, and biocompatibility.
A new type of antibacterial bone cement incorporating surface stereochemistry and the antibacterial monomer isobornyl acrylate (BA) is reported. In this study, BA was integrated into poly(methyl methacrylate) (PMMA) bone cement through liquid-phase modification to create a non-leaching antibacterial bone cement (NLBC). The maximum temperature, setting time, antibacterial activity, mechanical strength, and biocompatibility of this NLBC were comprehensively evaluated. The results showed that the BA cement exhibited exceptional antibacterial activity and mechanical properties. The 30 wt% BA cement demonstrated an antibacterial activity of 81.0 ± 3.1% against Staphylococcus aureus and a compressive strength of 72.10 ± 1.97 MPa. The BA cement exhibited good biocompatibility both in vitro and in vivo. Furthermore, we compared the antibacterial activity, mechanical properties, and biocompatibility of the BA cement with those of three previously reported bone cements, which contain the antibacterial monomers 2-(tert-butylamino)ethyl methacrylate (TBAEMA), methacrylate derived from benzothiazole (BTTMA), and nitrofuran methacrylate (NFMA), respectively. The findings of this study have important implications for the advancement of antibacterial bone cement and its application in medical implants.
Antibiotic-loaded PMMA (polymethylmethacrylate) bone cement (ALBC) is widely used to prevent and treat periprosthetic joint infections (PJIs), yet its clinical efficacy is limited by issues like burst release and short release duration. To address these challenges, this study developed a composite bone cement (HV-PMMA) loaded with vancomycin-functionalized halloysite nanotubes (HNTs-Van). The results showed that HV-PMMA optimized antibiotic elution: it avoided initial burst release, and the drug elution amount of HV-PMMA was superior to that of traditional ALBC with vancomycin formulation. The addition of HNTs-Van slightly reduces the compressive strength of the bone cement. Importantly, HV-PMMA maintained good biocompatibility, with a hemolysis rate below 5% and no acute systemic toxicity. This nano-scale physical drug-loading strategy effectively solves the limitations of traditional ALBC, providing an efficient and safe approach for designing antibacterial bone cements to prevent and treat PJIs.
The tendon-sheath actuated system (TSAS) has been widely adopted in many cases due to its merits of compliance, dexterity, and remote transmission. However, realizing precise control of the distal end poses remains a significant challenge due to inherent nonlinear phenomena caused by friction and hysteresis. In this study, a novel adaptive sliding mode compensation control (ASMCC) scheme based on the inverse transmission model was proposed to achieve accurate trajectory tracking of the TSAS. Based on the Coulomb friction model, the static and dynamic models of TSAS were analyzed and the correctness of system’s output displacement and output force characteristics was confirmed through simulation and experimental results. Based on the assumptions of the constant curvature of the sheath and the pre-tensioned tendon, the inverse model was calibrated by offline measurements with sensors installed at the proximal end. A novel control strategy was developed based on the inverse model combined with an adaptive algorithm according to Lyapunov stability theory with sliding mode controller for the online estimation of time-varying parameters. Finally, trajectory tracking experiments were conducted with/without external springs to evaluate the feasibility of the proposed control strategy, and its effectiveness and accuracy in parameter identification and accuracy compensation for the single tendon-sheath actuated system was confirmed.